The Board of Directors of Jubilant Pharmova Limited, at their meeting held on May 22, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. For the quarter ended March 31, 2026, the company reported revenue from operations of 22,900 million compared to 21,225 million in the preceding quarter (December 31, 2025) and 19,158 million in the corresponding quarter of the previous year (March 31, 2025). Profit after tax for the current quarter stood at 55.8 million. The comparative financial analysis is detailed below:

Jubilant Pharmova Limited is an integrated global pharmaceuticals company that operates across three primary business segments: pharmaceuticals, contract research and development services, and proprietary novel drugs. Headquartered in New Delhi, the company has a strong international footprint and is a significant manufacturer in the radiopharmaceutical space, maintaining a notable network of radiopharmacies, particularly in North America. Recent updates include the appointment of Mr. Ashish Mukkirwar as the new Chief Financial Officer, effective May 23, 2026, succeeding Mr. Arun Kumar Sharma, who has transitioned to the role of Advisor to the Chairmen. Additionally, the Board has re-appointed Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director for a three-year term effective June 1, 2026. In 2025, the company continued its focus on operational expansion, including a $50 million investment to expand its PET radiopharmacy network and receiving various approvals for its manufacturing facilities from the USFDA. The company is part of the Jubilant Bhartia Group, and its leadership continuity remains a key focus for shareholders.